eligibility_summary
Eligible: adults 18–70 with ECOG 0–1, life expectancy ≥12 weeks, adequate organ function, informed consent, disease progression documented by imaging before tumor sampling if applicable, ≥1 measurable RECIST v1.1 lesion after sampling. Exclude: uncontrolled tumor pain, unstable analgesia, pending palliative RT, mental illness or alcohol/substance abuse, pregnancy/lactation or pregnancy plans within 1 year, trial drugs within 4 weeks pre-lymphodepletion or during study, any condition deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT06235242 tests: 1) GT201, an autologous tumor‑infiltrating lymphocyte (TIL) cell therapy. Mechanism: patient’s tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor neoantigens via TCR–MHC and kill cancer cells (primarily cytotoxic CD8+ activity). Drug type: cellular immunotherapy. 2) Teraplizumab, a monoclonal antibody immune checkpoint inhibitor. Mechanism: blocks inhibitory receptor–ligand signaling to restore/boost antitumor T‑cell function (PD-1/PD-L1 pathway blockade intended). Drug type: biological mAb. Targets/pathways: tumor-reactive T cells within the tumor microenvironment, TCR-mediated cytotoxicity (perforin/granzyme), T‑cell checkpoint pathways driving exhaustion/inhibition.